- Global Pharma News & Resources

Scottish patients with incurable breast cancer get access to Perjeta

SMC recommends use of life-extending medicine

Monday 14 January: The Scottish Medicines Consortium (SMC) has today recommended that Perjeta® (pertuzumab) should be made available to HER2-positive metastatic breast cancer patients on the NHS. Metastatic breast cancer, also known as stage IV or secondary breast cancer, is when the disease has spread to other parts of the body. Although metastatic breast cancer can’t be cured it can be treated.1


An estimated 983 patients per year in Scotland could be eligible to receive Perjeta in the metastatic setting.2


Dr Iain Macpherson, Consultant Medical Oncologist at The Beatson Cancer Centre in Glasgow said: “Currently in Scotland, we treat HER2-positive metastatic breast cancer with trastuzumab and chemotherapy. The addition of Perjeta has been shown to increase the survival of these patients by 15.7 months on average compared to our current standard of care. The decision is great news for Scottish patients with HER2-positive metastatic breast cancer and could mean valuable additional time to spend with their friends and family.”


Richard Erwin, Roche’s General Manager said: “We’re very pleased that Perjeta will now be available to metastatic breast cancer patients in Scotland. Perjeta was also recently approved for use in the neoadjuvant, or pre-surgery, setting by SMC and we will be submitting for approval in the adjuvant, or post-surgery, setting later this year. We look forward to a continuing to build on our successful and productive relationship with SMC to benefit all appropriate breast cancer patients.”  


Perjeta is licensed for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.3


Perjeta has been shown to be an effective treatment for HER2-positive metastatic breast cancer. In the CLEOPATRA study involving 808 patients with previously untreated HER2-positive metastatic breast cancer, the primary endpoint was independently assessed progression-free survival (PFS). Median PFS was 18.5 months in the Perjeta group compared to 12.4 months in the control group (hazard ratio for progression or death, 0.62; 95% CI, 0.51 to 0.75; P<0.001).4

Final data from a key secondary endpoint of the CLEOPATRA trial showed that Perjeta extended the lives of patients by 15.7 months, compared to the control group (hazard ratio for overall survival 0.68; 95% CI, 0.56 to 0.84; P<0.001, median overall survival was 56.5 vs. 40.8 months). Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained.5

Editor Details

Last Updated: 14-Jan-2019